Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WNT1 | P04628 | 4/20 | 0.34 |
| ▸ | GSK3B | P49841 | 4/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 4/20 | 0.34 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.31 |
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
| ▸ | JAK1 | P23458 | 1/20 | 0.31 |
| ▸ | TYK2 | P29597 | 1/20 | 0.31 |
| ▸ | JAK3 | P52333 | 1/20 | 0.31 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.31 |
| ▸ | CLK2 | P49760 | 1/20 | 0.30 |
| ▸ | CLK3 | P49761 | 1/20 | 0.30 |
| ▸ | APP | P05067 | 1/20 | 0.30 |
| ▸ | BACE1 | P56817 | 1/20 | 0.30 |
| ▸ | ABL1 | P00519 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20959598 | 1.00 | WNT1 (0.34) | WNT1GSK3BDYRK1AIRAK4P2RX7 | |
| SCHEMBL20980308 | 0.90 | STK17B (0.35) | WNT1GSK3BDYRK1AIRAK4BACE1 | |
| SCHEMBL20980306 | 0.90 | STK17B (0.35) | WNT1GSK3BDYRK1AIRAK4BACE1 | |
| SCHEMBL16036398 | 0.89 | TP53 (0.33) | — | |
| SCHEMBL20913352 | 0.88 | TP53 (0.35) | — | |
| SCHEMBL20959635 | 0.83 | GSK3B (0.32) | WNT1GSK3BDYRK1AIRAK4P2RX7 | |
| SCHEMBL20913365 | 0.83 | GSK3B (0.32) | WNT1GSK3BDYRK1AIRAK4P2RX7 | |
| SCHEMBL4549858 | 0.79 | STK17B (0.38) | GSK3BDYRK1AABL1 | |
| SCHEMBL29620330 | 0.79 | STK17B (0.38) | GSK3BDYRK1AABL1 | |
| SCHEMBL30926497 | 0.79 | STK17B (0.37) | GSK3BDYRK1AP2RX7ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3858835-A1 | PYRIMIDINE-BASED ANTIPROLIFERATIVE AGENTS | G1 Therapeutics, Inc. (US) | 2021-08-04 | — | — | EP | disclosed |
| US-20210047328-A1 | PYRIMIDINE-BASED ANTIPROLIFERATIVE AGENTS | G1 THERAPEUTICS, INC. (US) | 2021-02-18 | — | — | US | disclosed |
| US-10829490-B2 | Substituted dihydropyrazino[1 ′,2′:1,5]pyrrolo[2,3-d]pyrimidine-based antiproliferative agents | GI Therapeutics, Inc. (US) | 2020-11-10 | — | — | US | disclosed |
| US-20190135811-A1 | PYRIMIDINE-BASED ANTIPROLIFERATIVE AGENTS | G1 THERAPEUTICS, INC. (US) | 2019-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190135811-A1 | PYRIMIDINE-BASED ANTIPROLIFERATIVE AGENTS | TYMP, TYMS, DPYD | WNT1 523/4885GSK3B 2324/4885DYRK1A 1245/4885 |
| US-20210047328-A1 | PYRIMIDINE-BASED ANTIPROLIFERATIVE AGENTS | TYMP, TYMS, DPYD | WNT1 523/4885GSK3B 2324/4885DYRK1A 1245/4885 |
| US-10829490-B2 | Substituted dihydropyrazino[1 ′,2′:1,5]pyrrolo[2,3-d]pyrimidine-based antiproliferative agents | MKI67, DPYD, PCNA | WNT1 251/4885GSK3B 1634/4885DYRK1A 1586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.